Koninklijke Philips (PHG) Eyeing Potential in Corindus Vascular Robotics (CVRS); Kronos Worldwide (KRO) Posts Profits


Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) shares surged over 10% in the extended session Friday after health technology giant Koninklijke Philips N.V. (NYSE:PHG) disclosed in a regulatory filing ( SC 13D ) with the Securities and Exchange Commission (SEC) a 15.5% stake (29,693,444 shares) in the company.

CVRS stock closed at $1.08, up $0.03 (or +2.86%) and 1.23M of its shares changed hands during the day.

Corindus Vascular Robotics, which designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures, has 119.03M shares outstanding, market capitalization (intraday) of $123.83M and CVRS stock 52-week range is between $0.40 and $1.80 per share.



Shares of Kronos Worldwide, Inc. (NYSE:KRO) climbed more than 5% in after-hours trading Friday as the company delivered robust profit growth in its quarterly financial results.

For the fourth quarter 2016, Kronos posted net sales of $333.7 million, a 16.27% increase year over year, and net income of $23.2 million, or $0.20 per share versus a net loss of ($20.4) million, or ($0.18) per share in the same period the prior year.

KRO finished the regular session at $13.97, down $0.03 (or -0.21%) with a total volume of 499,664 shares traded.

Kronos Worldwide, which produces and markets titanium dioxide pigments (TiO2) worldwide, has 115.89M shares outstanding, market capitalization (intraday) of $1.62B and KRO stock one-year range is from $4.70 to $15.80 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/